Citations

Showing 10 of 107863 citations.

A Comprehensive Analysis of Predictors of Marginal Ulcers After Roux-en-Y Gastric Bypass: A Cohort Review of 2106 Patients
Abedalqader, Tala, Migliorini, Alberto, Cerecedo, Leonardo Garcia , Ghazal, Nour El , Klim, Joseph , Boutros, Tony, Laplante, Simon , Ghanem, Omar M., El Ghazal, Nour , Laplante, Simon J , Abedalqader, Tala , Ghanem, Omar M.

Mayo Clinic

Medicina | April 29, 2026 | Volume: 62 | Issue: 5 | Pages: 838

10.3390/medicina62050838 | PMID 42195091 Get It

Background and Objectives: Roux-en-Y gastric bypass (RYGB) is one of the most commonly performed metabolic and bariatric surgeries worldwide. Marginal ulcers (MU) are a common complication following RYGB, yet their pathophysiology and the contributing risk factors to their development are not fully understood. Materials and Methods: This retrospective cohort study examined patients who underwent RYGB between January 2008 and December 2023, with 1 to 5 years of follow-up. Data collected included patient- and procedure-related risk factors, as well as postoperative MU events. Statistical analysis methods included the independent samples t-tests, multivariate regression, and Cox regression analyses. Results: Our final cohort included 2106 patients and was predominantly female (80.5%), with a mean age of 47.8 ± 12.1 years and body mass index (BMI) of 45.5 ± 7.5 kg/m2. MU occurred in 241 (11.4%) patients, with a mean time to occurrence of 4.5 ± 0.02 years. History of smoking (HR = 1.87, p < 0.001) and gastroesophageal reflux disease (HR = 2.36, p < 0.001) significantly increased hazard for MU, while proton pump inhibitor use (HR = 0.18, p < 0.001) was associated with reduced hazard. Aspirin exposure, regardless of dose and chronicity, did not impact MU. Conclusions: Our findings highlight the importance of preoperative assessment and counseling in patients planning to undergo RYGB. Patient-related factors should guide postoperative monitoring and prophylaxis of MU, as this remains a debated topic amongst experts.
Steroid Refractory and Plasma Exchange Partially Responsive Longitudinally Extensive Transverse Myelitis Due to Tumor Necrosis Factor-Alpha (Etanercept): A Case Report
Stojsavljevic, Jelena, Perez, Rafael R., Petcu, Emilia, Odenigbo, Celestine , Madrid, Cristian , Dumic, Igor , Nordstrom, Charles W. , Dumic, Igor , Nordstrom, Charles W , Petcu, Emilia

Mayo Clinic

Clinics and Practice | April 29, 2026 | Volume: 16 | Issue: 5 | Pages: 86

10.3390/clinpract16050086 | PMID 42187520 Get It

Background: Acute transverse myelitis (ATM) is an inflammatory disorder of the spinal cord with heterogeneous etiologies, including autoimmune, infectious, paraneoplastic, and drug-induced causes. Tumor necrosis factor-alpha (TNF-α) inhibitors have been infrequently associated with inflammatory central nervous system events, including transverse myelitis. TNF-inhibitor-associated myelitis typically presents with short-segment lesions, a normal brain MRI, and partial responsiveness to corticosteroids. Longitudinally extensive transverse myelitis (LETM) and steroid-refractory cases are uncommon. Case Presentation: A 39-year-old woman with psoriatic arthritis treated with etanercept for two years presented with subacute progressive bilateral lower-extremity sensory loss and weakness. MRI revealed a T2 hyperintense spinal cord lesion extending from T11 to L1 with gadolinium enhancement, consistent with transverse myelitis, while brain MRI was normal. Cerebrospinal fluid analysis showed lymphocytic pleocytosis, elevated protein, oligoclonal bands, and increased kappa free light chains. Extensive infectious, metabolic, paraneoplastic, and autoimmune testing, including aquaporin-4 and MOG antibodies, was negative. Despite high-dose intravenous corticosteroids and the discontinuation of etanercept, the patient experienced clinical worsening with lesion expansion, meeting criteria for LETM, and developed urinary retention. She subsequently underwent plasma exchange, resulting in radiologic improvement and moderate clinical recovery. Conclusions: This case highlights an atypical presentation of TNF-inhibitor-associated myelitis characterized by a biphasic course, longitudinally extensive spinal cord involvement, steroid refractoriness, and responsiveness to plasma exchange. These features suggest either an unusually severe TNF-inhibitor-related inflammatory phenotype or a TNF-inhibitor-triggered antibody-mediated demyelinating process. Reports of TNF-inhibitor-associated myelitis evolving into longitudinally extensive, steroid-refractory disease remain limited, and this presentation may broaden the recognized clinical spectrum of TNF-α-related CNS inflammatory events. Close neurologic follow-up and heightened awareness of severe CNS complications associated with TNF-α inhibitors are warranted.
How to Avoid Tunnel Convergence of Anterior Cruciate Ligament and Lateral Collateral Ligament/Posterolateral Corner Sockets in Multiligament Knee Reconstructions
Bishop, Alexander K. , Rechter, Griffin R. , Levy, Brooke R., Hevesi, Mario , Krych, Aaron J. , Tagliero, Adam J. , Levy, Bruce A. , Krych, Aaron J , Tagliero, Adam , Hevesi, Mario , Bishop, Alexander

Mayo Clinic

Arthroscopy Techniques | April 29, 2026 | Volume: 15 | Issue: 7 | Pages: No page available

10.1002/atn2.70040 | PMID 42519634 Get It

Abstract Tunnel convergence in multiligament knee surgery remains a technical challenge. Anterior cruciate ligament (ACL) femoral sockets/tunnels and lateral collateral ligament (LCL) femoral sockets/tunnels during anatomic posterolateral corner (PLC) reconstructions are particularly vulnerable to convergence. This is secondary to the limited amount of bony real estate available on the lateral distal femur. Previous studies have attempted to define a specific angle to direct the LCL tunnel away from the ACL tunnel. However, inconsistency with ACL femoral socket creation and variability in bony architecture can make this strategy unreliable. This surgical technique describes how to minimize the risk of ACL and LCL tunnel convergence during ACL and PLC reconstructions.
Percutaneous spinal stimulation to enhance gait and alleviate functional impairments in multiple sclerosis: A pilot study
Jahanian, Omid , Asp, Anders J., Gill, Megan L., Veith, Daniel D. , Fernandez, K. A. , Hogen, Cecilia A., Mills, Candee J. , Thoreson, Andrew R. , Grahn, Peter J. , Fernandez, Katrina A, Tobin, W Oliver , Fernandez, K A , Jahanian, Omid , Asp, Anders J., Solinsky, Ryan , Kaufman, Kenton R. , Zhao, Kristin D. , Tobin, W. Oliver

Mayo Clinic

Multiple Sclerosis Journal – Experimental, Translational and Clinical | April 29, 2026 | Volume: 12 | Issue: 2 | Pages: No page available

10.1177/20552173261432301 | PMID 42112095 Get It

Objective To evaluate the feasibility and potential efficacy of percutaneous spinal stimulation (epidural stimulation, ES) combined with task-specific training to reduce spasticity and improve gait and balance in individuals with progressive multiple sclerosis (MS). Methods Two men with progressive MS (EDSS 6.5) underwent ES lead implantation targeting the lower spinal cord, followed by one month of rehabilitation involving 12 ES-assisted training sessions. Assessments included instrumented gait analysis, Modified Ashworth Scale (MAS), pendulum test, and static balance testing performed at baseline, and at end of the study with ES-Off and ES-On conditions. Results Participant 1, with spastic hemiparetic gait, demonstrated improved lower extremity joint kinematics and muscle activation during gait, reduced knee extensor spasticity, and enhanced functional movement patterns with ES-On. Participant 2, with significant paraparesis and minimal spasticity, showed limited gait changes but experienced marked improvements in static balance, particularly under eyes-closed conditions. No adverse events were reported. Conclusion This pilot study demonstrates the feasibility and tolerability of ES paired with task-specific training in progressive MS. Participant-specific responses were observed, including improvements in gait kinematics, neuromuscular activation, spasticity, or balance; however, spatiotemporal gait parameters did not improve. These preliminary findings highlight response heterogeneity and the need for individualized ES parameter tuning. Trial registry name and URL: https://clinicaltrials.gov/study/NCT06019611
The Association of Microplastics in Peripheral Blood and Pulmonary Disease: A Pilot Study
Helgeson, Scott A. , Alaws, Hossny, Ibrahim, Mohamed I. , Lee, Augustine S., Vlecken, Danielle H. W. , Baig, Hassan , Lee, Augustine S. , Lee, Augustine S , Baig, Hassan Z , Helgeson, Scott A , Vlecken, Danielle H. W.

Mayo Clinic

Journal of Xenobiotics | April 29, 2026 | Volume: 16 | Issue: 3 | Pages: 72

10.3390/jox16030072 | PMID 42201067 Get It

Microplastics may pose health risks, particularly for chronic lung diseases. Clarifying the link between circulating microplastics and pulmonary disease is vital for shaping research and interventions. The objective of this study was to evaluate whether microplastics in peripheral blood are associated with COPD or IPF vs. no lung disease. In this pilot prospective case-control study, participants were grouped as control (n = 10), COPD (n = 9), or IPF (n = 10). Relevant comorbidities and exposures were obtained from records and questionnaires. All underwent standardized blood collection (PlasticTox©). Samples were analyzed for total microplastic concentration, stratified by size (<10 µm, 10–30 µm, 30–70 µm). The primary outcome was to show a difference in total microplastic burden between lung disease and controls. Secondary measures were to determine size-specific concentrations and associations with demographic variables and smoking history. Among 29 participants (median age 70 (IQR 64–80); 14 women (48.3%)), COPD/IPF groups had significantly higher total microplastic concentrations vs. controls (median 26.0 vs. 3.5 particles/100 µL; p < 0.01). Particle burdens <10 µm and 10–30 µm were particularly elevated (both p < 0.01). After adjusting for smoking, only the <10 µm fraction remained independently associated with lung disease (adjusted odds ratio 1.94 (95% CI, 1.23–7.04)). In this pilot exploratory study, individuals with COPD or IPF showed greater circulating microplastic levels than controls. These findings should be interpreted as hypothesis-generating, and larger analytically validated studies are needed to clarify directionality, causal mechanisms, contamination control, and the clinical relevance of circulating microplastic burden.
Dose Accuracy and Content Uniformity of Low-Dose Metoprolol Tablets: 3D Printing Compared with Tablet Splitting in Hospital Pharmacy Setting
Larsen, Christine , Shokraneh, Farnaz , Lahtinen, Julius , Bahman, Mahsa, Mantila, Laura, Hrizanovska, Ludmila, Sandler, Niklas, Larsen, Christine, Bahman, Mahsa

Mayo Clinic

Pharmaceutics | April 29, 2026 | Volume: 18 | Issue: 5 | Pages: 532

10.3390/pharmaceutics18050532 | PMID 42198226 Get It

Background: Tablet splitting is widely used to individualize dosing of metoprolol tartrate when low-dose formulations are unavailable. However, splitting may lead to variability in dose accuracy, which can be clinically relevant at low dose strengths. This study compared the accuracy and precision of manual tablet splitting versus automated 3D printing for producing low-dose metoprolol tartrate tablets in a hospital setting. Methods: Commercial 25 mg metoprolol tartrate tablets from two manufacturers were manually split at Mayo Clinic into 12.5 mg halves and 6.25 mg quarters following established procedures. CurifyLabs’ Compounding System, including the Pharma Printer and CuraBlend®-based formulations, was used at two hospital pharmacy sites and a compounding pharmacy to produce 6.25 mg and 12.5 mg tablets via 3D printing. Mass variation and content uniformity were evaluated using USP <905> criteria and validated HPLC methods. Results: Manually split tablets showed high variability, with 6.25 mg quarters ranging from 24.9% to 142.8% API content and 12.5 mg halves from one manufacturer averaging only 66.6%, indicating frequent underdosing. In contrast, 3D-printed tablets achieved mean API contents within 90–103%, standard deviations below 5%, and acceptance values under 15 across all sites and formulations. Conclusion: Manual tablet splitting may not reliably meet pharmacopeial expectations for dose accuracy and content uniformity at lower dose strengths. Automated 3D printing produced consistent low-dose tablets and may offer a validated alternative where available.
Evaluation of a Rapid Lateral Flow Assay for Coccidioidomycosis to Monitor Antibody Levels in Patients Using Fingerstick Capillary Blood
Grill, Francisca J. , Pedersen, Karen, Reilly, Kenta, Lake, Douglas F. , Blair, Janis E. , Lake, Douglas F , Blair, Janis E , Reilly, Kenta S., Grys, Thomas E.

Mayo Clinic

Journal of Fungi | April 29, 2026 | Volume: 12 | Issue: 5 | Pages: 326

10.3390/jof12050326 | PMID 42187808 Get It

The diagnosis of coccidioidomycosis is often achieved serologically by the detection of antibodies against fungal antigens. While several serologic tests are available for coccidioidomycosis, all of them are performed in a laboratory setting causing delays in diagnosis and therapeutic intervention. Point-of-care testing offers the ability to provide a shorter time to result by avoiding specimen send-out, minimizing processing steps, and employing expeditious immunochemical techniques. A preliminary trial of a rapid anti-coccidioidal antibody lateral flow assay (LFA) using fingerstick blood was performed on 22 patients with coccidioidomycosis at the point of care during outpatient clinic visits. Patients were tested longitudinally over the course of one year. An LFA reader was implemented to provide an objective result by quantifying the intensity of the test line band. There was close qualitative concordance observed between positive LFA results with send-out immunodiffusion (89.5%) and complement fixation (78.4%) standard of care clinical laboratory assays. Additionally, the relationship between LFA test line density values and traditional complement fixation antibody titers was assessed.
Beyond the Basics: Revision Hip Capsular Management and Advanced Closure Technique
Hayden, Alexander C. , Ina, Jason , Cabarcas, Brandon , Krych, Aaron J. , Hevesi, Mario , Cabarcas, Brandon C. , Ina, Jason G , Krych, Aaron J , Hevesi, Mario , Ward, Gavin H.

Mayo Clinic

Arthroscopy Techniques | April 29, 2026 | Volume: 15 | Issue: 1 | Pages: No page available

10.1002/atn2.70014 | PMID 42383244 Get It

Hip arthroscopy is an increasingly common procedure to treat intra‐articular conditions such as labral tears and femoroacetabular impingement. With the increase in frequency of such procedures, so too are revision arthroscopic hip procedures. Capsular repair in the setting of revision hip arthroscopy can be challenging due to the presence of adhesions and scar tissue formation that obscure tissue planes, suboptimal quality of residual capsular tissue, and the presence of capsular tissue defects. This technical note aims to describe the key surgical principles and considerations of revision hip capsular closure.
Explainable Agentic Artificial Intelligence in Healthcare: A Scoping Review
Collaço, Bernardo Gabriele , Prabha, Srinivasagam, Gomez-Cabello, Cesar A., Haider, Syed Ali , Wood, Nadia , Gopala, Narayanan, Raman, Raghunath, Hester, Erik O., Forte, Antonio J. , Collaco, Bernardo G , Wood, Nadia , Forte, Antonio Jorge , Haider, Syed A , Prabha, Srinivasagam , Gomez-Cabello, Cesar A. , Genovese, Ariana

Mayo Clinic

Bioengineering | April 29, 2026 | Volume: 13 | Issue: 5 | Pages: 513

10.3390/bioengineering13050513 | PMID 42194270 Get It

Background: Agentic artificial intelligence (AI) systems, characterized by autonomous goal-directed behavior, multi-step reasoning, task decomposition, and tool use, are increasingly proposed for healthcare applications. However, their autonomy raises concerns regarding transparency, accountability, and human oversight. While explainable AI (XAI) has been widely studied in traditional predictive models, less is known about how explainability is implemented within agentic architectures. Objective: To map the emerging literature on explainable agentic AI (XAAI) in healthcare and characterize the types, scope, and forms of explainability used in these systems. Methods: A scoping review was conducted following PRISMA-ScR guidelines. PubMed, Embase, IEEE Xplore, and ACM Digital Library were searched through November 2025. Eligible studies described healthcare-related agentic AI systems incorporating explicit explainability mechanisms. Data were extracted on system architecture, explainability type (intrinsic, post hoc, hybrid), explanation scope (local, global), explanation form, and reported clinical outcomes. Results: Nine studies met the inclusion criteria. All systems demonstrated core agentic features, including autonomy, task decomposition, and tool integration, often within multi-agent frameworks. Explainability was predominantly intrinsic and workflow-native, typically delivered through textual reasoning traces and example-based grounding in retrieved clinical evidence. Feature-based and global explanations were comparatively rare and largely confined to hybrid architectures. Across domains including radiology, neurology, psychiatry, and biomedical research, XAAI systems were reported to improve performance and interpretability relative to baseline models in the included studies. However, these findings were derived from heterogeneous, predominantly experimental or retrospective studies, and structured human-in-the-loop oversight was infrequently described. Conclusions: Current XAAI systems appear to emphasize process transparency and evidence grounding rather than mechanistic model-level attribution. The available evidence remains limited and heterogeneous, and findings should be interpreted as early trends rather than established characteristics. Further progress will require standardized evaluation frameworks, clearer reporting of oversight mechanisms, and validation in real-world clinical settings to support safe and trustworthy integration of agentic AI into healthcare practice.
Intra‐Articular Purified Exosome Product and Hyaluronan Attenuate Osteoarthritis Progression in a Minimally Invasive Turkey Model
Lei, Xing , Wang, Lei, Reisdorf, Ramona L., Brosig, Maggie A, Moran, Steven L, Evans, CH, Zhao, Chunfeng, Brosig, Maggie, Moran, Steven L., Evans, Christopher H., Zhao, Chunfeng

Mayo Clinic

Journal of Orthopaedic Research | April 29, 2026 | Volume: 44 | Issue: 5 | Pages: No page available

10.1002/jor.70207 | PMID 42051070 Get It

ABSTRACT Our study aimed to develop a novel, reproducible, minimally invasive turkey knee osteoarthritis (OA) model and evaluate whether intra‐articular hyaluronan (HA) alone or combined with purified exosome product (PEP) attenuates OA‐related functional and structural deterioration. OA was induced arthroscopically by transection of the anterior and posterior cruciate ligaments with resection of the anterior horn of the medial meniscus. Animals received intra‐articular injections of saline, HA, or PEP + HA at postoperative 2–5 weeks. Gait was assessed at 4, 8, and 12 weeks, and cartilage degeneration, subchondral bone sclerosis, osteophyte formation, synovial fibrosis, heterotopic ossification, and meniscal integrity were evaluated by quantitative CT and histology at week 12. Compared with saline, HA improved lameness, preserved cartilage glycosaminoglycan content, and reduced meniscal rupture, subchondral bone sclerosis, and periarticular heterotopic ossification. PEP + HA provided additional benefits, including prolonged stance phase, reduced synovial fibrosis, and greater chondroprotection than HA alone, while plantar pressure variables, subchondral bone remodeling, and patellar osteophytes did not differ between HA and PEP + HA. This turkey model reliably produces human‐like OA changes and enables longitudinal functional and structural assessment. Intra‐articular HA mitigated OA progression, and the addition of PEP conferred incremental joint protection.